title: High doses of botulinum toxin effectively treat disabling up-going toe.
abstract: Involuntary up-going toe can be a disabling consequence of dystonia or spasticity. In this study, we treated eight patients with botulinum toxin (BTx) in the extensor hallucis longus (EHL) and applied objective and subjective outcome measures to determine treatment efficacy. Using 100% higher doses than generally reported, patients noted 62+/-20% mean benefit and scores on a modified Fahn-Marsden Dystonia Scale decreased significantly by 1.8+/-0.6 (p=0.010). High doses (up to 160 BTx A units) into the EHL were safe and dosage correlated highly and significantly with treatment efficacy (rho=0.859, p=0.006).
authors: Clinical Motor Physiology Laboratory, Department of Neurology, Columbia University Medical Center, New York, NY, USA.
authors: M M
authors: MM
authors: Kurtis
authors: A G
authors: AG
authors: Floyd
authors: Q P
authors: QP
authors: Yu
authors: S L
authors: SL
authors: Pullman
mesh_terms: D000328:Adult; D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage; D001905:Botulinum Toxins / Q000008:administration & dosage*; D002648:Child; D004305:Dose-Response Relationship, Drug; D020821:Dystonic Disorders / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000503:physiopathology; D014034:Toes / Q000294:innervation / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins